Clearmind Medicine (CMND) Competitors $1.20 +0.01 (+0.84%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CMND vs. BCLI, AYTU, EGRX, VIRX, ENSC, ADXN, BFRI, OBSV, COEP, and CEROShould you be buying Clearmind Medicine stock or one of its competitors? The main competitors of Clearmind Medicine include Brainstorm Cell Therapeutics (BCLI), Aytu BioPharma (AYTU), Eagle Pharmaceuticals (EGRX), Viracta Therapeutics (VIRX), Ensysce Biosciences (ENSC), Addex Therapeutics (ADXN), Biofrontera (BFRI), ObsEva (OBSV), Coeptis Therapeutics (COEP), and CERo Therapeutics (CERO). These companies are all part of the "pharmaceutical products" industry. Clearmind Medicine vs. Brainstorm Cell Therapeutics Aytu BioPharma Eagle Pharmaceuticals Viracta Therapeutics Ensysce Biosciences Addex Therapeutics Biofrontera ObsEva Coeptis Therapeutics CERo Therapeutics Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership. Do analysts rate BCLI or CMND? Brainstorm Cell Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 1,215.79%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Clearmind Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, BCLI or CMND? Brainstorm Cell Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Clearmind Medicine has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Is BCLI or CMND more profitable? Brainstorm Cell Therapeutics' return on equity of 0.00% beat Clearmind Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Brainstorm Cell TherapeuticsN/A N/A -528.56% Clearmind Medicine N/A -238.73%-102.10% Do insiders and institutionals have more ownership in BCLI or CMND? 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are held by institutional investors. 6.7% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer BCLI or CMND? Brainstorm Cell Therapeutics received 291 more outperform votes than Clearmind Medicine when rated by MarketBeat users. CompanyUnderperformOutperformBrainstorm Cell TherapeuticsOutperform Votes29161.26% Underperform Votes18438.74% Clearmind MedicineN/AN/A Which has preferable valuation and earnings, BCLI or CMND? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBrainstorm Cell TherapeuticsN/AN/A-$17.19M-$4.80-0.48Clearmind MedicineN/AN/A-$8.62MN/AN/A Does the media refer more to BCLI or CMND? In the previous week, Clearmind Medicine had 2 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 2 mentions for Clearmind Medicine and 0 mentions for Brainstorm Cell Therapeutics. Clearmind Medicine's average media sentiment score of 0.66 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media. Company Overall Sentiment Brainstorm Cell Therapeutics Neutral Clearmind Medicine Positive SummaryBrainstorm Cell Therapeutics and Clearmind Medicine tied by winning 6 of the 12 factors compared between the two stocks. Ad InvestorPlaceWall Street Icon: “You must get on the right side of this thing”I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.This market shakeup is going to be much more intense. Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMND vs. The Competition Export to ExcelMetricClearmind MedicinePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.03M$6.58B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E RatioN/A10.5489.7417.18Price / SalesN/A195.791,116.12116.95Price / CashN/A57.1642.8237.86Price / Book0.285.094.774.78Net Income-$8.62M$151.83M$120.15M$225.60M7 Day Performance-18.55%-2.13%-1.92%-1.23%1 Month Performance-10.45%-3.10%11.47%3.36%1 Year Performance-61.54%11.54%30.52%16.60% Clearmind Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMNDClearmind Medicine0.4682 of 5 stars$1.20+0.8%N/A-61.5%$2.03MN/A0.00N/ABCLIBrainstorm Cell Therapeutics3.9873 of 5 stars$1.55+6.9%$30.00+1,835.5%-21.2%$8.84MN/A-0.3040Gap UpAYTUAytu BioPharma0.8898 of 5 stars$1.40-2.8%N/A-52.9%$8.61M$81M-1.17160Positive NewsEGRXEagle Pharmaceuticals1.004 of 5 stars$0.65-13.3%N/A-89.0%$8.44M$257.55M0.00134Gap DownVIRXViracta Therapeutics2.5296 of 5 stars$0.21+4.6%$5.00+2,258.5%-56.7%$8.43MN/A-0.1820Gap DownENSCEnsysce Biosciences0.0873 of 5 stars$6.41+14.1%N/A-49.1%$8.37M$2.23M-0.2010ADXNAddex Therapeutics2.7065 of 5 stars$7.85-1.9%$30.00+282.2%+39.1%$8.32M$556,045.00-23.5330Gap DownBFRIBiofrontera1.4519 of 5 stars$1.04-1.9%$7.00+573.1%-69.7%$8.06M$35.36M-0.4770Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastNews CoverageCOEPCoeptis Therapeutics0.3751 of 5 stars$0.19+5.5%N/A-83.9%$7.85M$80,000.00-0.612Gap DownCEROCERo TherapeuticsN/A$0.05-10.1%N/AN/A$7.67MN/A0.008High Trading Volume Related Companies and Tools Related Companies BCLI Competitors AYTU Competitors EGRX Competitors VIRX Competitors ENSC Competitors ADXN Competitors BFRI Competitors OBSV Competitors COEP Competitors CERO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMND) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearmind Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
